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Aim: In this work, we use cationic organic nanocarriers as chemotherapy delivery 
platforms and test them in a colorectal cancer 3D in vitro model. Materials & 
methods: We used 3beta-(N-[N′,N′-dimethylaminoethane]carbamoyl])cholesterol 
(DC-chol) and dioleoylphosphatidylethanolamine (DOPE) liposomes and N-palmitoyl-
N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ) micelles, to
deliver AZD6244, a MEK inhibitor, to HCT116 cells cultured as monolayers and in 3D
in vitro cancer models (tumoroids). Results: Nanoparticle-mediated drug delivery was
superior to the free drug in monolayer experiments and despite their therapeutic
effect being hindered by poor diffusion through the cancer mass, GCPQ micelles were
also superior in tumoroids. Conclusion: These results support the role of nanoparticles
in improving drug delivery and highlight the need to include 3D cancer models in
early phases of drug development.
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Published online: 20 January 2016
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Colorectal cancer is the third most frequent 
cancer and ranks fourth for cancer-related 
deaths in the world [1]. Chemotherapy is 
used as an adjuvant treatment after patients 
undergo surgery but both therapeutic agents 
and delivery systems leave room for improve-
ment. One of the most promising targets 
for new generation chemotherapeutic agents 
is the MAPK pathway, and a number of 
inhibitors against various key proteins in this 
pathway are being developed.
The main limitations of conventional 
in vitro models of cancer (cell monolayers) 
are that they are not representative of cancer 
heterogeneity and that they do not account 
for the tumor microenvironment. Both 
these parameters influence cancer behav-
ior [2–4]. Additionally, cells in monolayers 
tend to be more sensitive to drugs, since 
their growth is subject to both tensile [5] 
and oxidative stress [6]. Inaccuracies at the 
in vitro and in vivo levels lead to a low rate 
of translational success in the clinic, despite 
therapeutics passing initial stages of drug 
development [7,8].
The use of 3D in vitro cancer models has 
revolutionized cancer research, allowing a 
more controlled environment for cell prolifer-
ation to be studied in the laboratory. Cultur-
ing cells in 3D elicits change in proliferation, 
behavior and protein expression compared 
with monolayers [9–11]. In addition, 3D can-
cer models allow drug penetration factors 
to be investigated [12,13]. The most com-
mon approach for 3D cell culture uses cells 
grown as spheroids. However promising, the 
highly cell-dense structure and thickness (in 
the range of hundreds of microns) of spher-
oid models tend to promote necrosis in the 
inner layers, due to the scarcity of nutrients 
and oxygen in their core [14]. One alternative 
is the use of natural scaffolds, which mimic 
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the tumor microenvironment and contain constituent 
proteins, such as collagen type I or hyaluronic acid [15–
17]. While the use of collagen type I hydrogels mimics 
the extracellular matrix and is a promising approach, 
its main limitation is the high water content [18]. 
Here we use a plastic compression technique to cre-
ate tumoroids, 3D in vitro models of colorectal can-
cer, by removing the excess water from collagen type I 
hydrogels. This model mimics the mechanical proper-
ties of real tissue better than uncompressed collagen 
hydrogels [9,19,20].
A number of organic nanoparticles have shown 
promising results in cancer therapy as delivery plat-
forms for chemotherapeutic drugs, with liposomes 
and micelles in the vanguard of development [21–24]. 
These carriers are particularly useful for the delivery of 
therapeutics with low water solubility [25].
Two of the most promising organic nanocarriers 
are cationic liposomes made from 3beta-(N-[N′,N′-
dimethylaminoethane] carbamoyl) cholesterol (DC-
chol) and dioleoylphosphatidylethanolamine (DOPE), 
which have been shown to have potential as nucleic acid 
and drug nanocarriers [26–28], and micelles made from 
N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-
trimethyl-6-O-glycolchitosan (GCPQ) , also cationic
in nature, which have been used to solubilize and
orally deliver hydrophobic molecules with high effi-
ciency [29–31]. Cationic nanoparticles have the advan-
tage of improving internalization by interacting with
the anionic cell surface [22,32,33]. However, only a few of
these nanoparticles have been tested in 3D in vitro can-
cer models, and most of these were spheroids [34–36].
A number of novel chemotherapeutic agents have 
been developed over the last years. Two of the most 
common target proteins for these therapies are MEK1 
and MEK2, key proteins of the MAPK pathway, par-
ticularly in cancers that have mutations in RAS or RAF 
since both molecules are upstream of MEK1/2 in the 
pathway. Here we explore the efficacy of AZD6244, an 
inhibitor of MEK1/2, in its free form as well as loaded 
in cationic liposomes and micelles, and we compare 
the efficacy of different formulations on cell monolay-
ers and tumoroids. We chose the cell line HCT116 for 
having a mutated KRAS that continuously activates 
the MAPK pathway. To our knowledge, this is the 
first time nanoparticles have been tested in a natural 
scaffold-based 3D in vitro cancer model.
Materials & methods
Nanoparticle fabrication
Liposomes were fabricated following a modified ver-
sion of Mozafari’s method [37]. Equimolar concentra-
tions (5 mM) of DOPE and DC-cholesterol (Avanti 
polar lipids, AL, USA) were dissolved in chloroform-
methanol (2:1), together with 2 mM AZD6244 or 
Nile Red, for drug toxicity and penetrations studies 
respectively, to a total of 9 ml. Solvents were removed 
by rotaevaporation to obtain a thin hydrophobic layer 
attached to the glass surface. That layer was rehydrated 
with 10 ml Milli-Q water, vortexed for 1 minand ultra-
sonicated for 5 min until fully detached. The resulting 
suspension was extruded through a 200 nm polycar-
bonate membrane using a liposome extruder (Avanti 
polar lipids) and dialyzed against Milli-Q water for six 
2-h cycles. Micelles were fabricated following a modi-
fied version of the protocol described in [29]. 20 mg of
GCPQ polymer (palmitoylation = 18.9%, quaternal-
ization = 11.2%, MW = 17,120 g/mol) were dispersed
in Milli-Q water either alone, with 2 mg of AZD6244
or with 0.5 mg of Nile Red for control toxicity, drug
toxicity and penetration studies, respectively. The
mixture was vortexed and sonicated for 1 min until
it became homogeneous and then probesonicated
with amplitude 45 for six 5-min cycles alternated with
3-min breaks (Qsonica, CT, USA) in an ice bath. The
newly formed GCPQ micelles were allowed to stabilize
for 15 min at room temperature before being filtered
through a 0.45 μm filter and centrifuged at 2000 x g to
remove nonencapsulated drug crystals.
Nanoparticle characterization
The drug content of both formulations was determined 
by HPLC against a standard curve of free AZD6244. 
Samples were diluted in methanol (1:3 for micelles and 
1:25 for liposomes) to break the nanoparticles open 
and then filtered through a 0.2 μm membrane prior to 
the chromatographic analysis. 30 μl of the sample were 
loaded into the loop and separated by reversed-phase 
chromatography using a Luna C18 column comprising 
5 μm beads, 4.6 mm diameter, 100 mm length, fitted 
with a Safeguard precolumn (Phenomenex, Cheshire, 
UK). The assays were performed at 25ºC, using a 
TM717 autosampler, a TM515 HPLC pump and a 
TM486 absorbance detector set at a wavelength of 260 
nm (Waters, Hertfordshire, UK). The mobile phase 
was HPLC grade methanol with an isocratic flow rate 
of 0.8 ml/min, and AZD6244 showed a retention time 
of 21.5 min under these conditions.
Dynamic light scattering (DLS) was used to deter-
mine the size of nanoparticle aggregates in an aque-
ous solution. A diluted suspension of nanoparticles 
was placed in a disposable cuvette and measured three-
times for 15 repeats each for size analysis in a Malvern 
Nanosizer ZS (Malvern, Worcestershire, UK).
Transmission electron microscopy (TEM) was 
used to visualize the particles at the nanoscale, and to 
determine their morphology and approximate size. An 
aqueous suspension of nanoparticles was placed on a 
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carbon grid and stained with a 1%w/v aqueous solu-
tion of uranyl acetate. TEM images were taken at a 
minimum of 30000X magnification using a Philips 
CM120 BioTwin transmission electron microscope 
(Philips, Eindhoven, The Netherlands) with a AMT 5 
megapixel digital camera (AMT, UK).
Cell maintenance
HCT116 human colorectal carcinoma cells were 
obtained from the European Collection for Cell Cul-
tures (Sigma-Aldrich, Dorset, UK) and routinely 
cultured in McCoy’s 5A medium supplemented with 
10%v/v foetal bovine serum, 100 U/ml penicillin 
and 100 μg/ml streptomycin (P/S) (Invitrogen, Pais-
ley, UK), at 37°C and in a 5%CO
2
/air humidified 
atmosphere.
Monolayer & tumoroid cell culture
For toxicity experiments in cell monolayers, 30,000 
cells/well were seeded in 24-well plates, fed with 500 μl 
of McCoy’s 5A medium supplemented with fetal bovine 
serum (FBS) and P/S and allowed to grow for 24 h 
before substituting the culture medium with serum-
free medium. Serum-free conditions minimize interac-
tions, such as agglomeration, between the free drug or 
nanoformulations with serum proteins; cell cycles were 
also semisynchronized. For toxicity and penetration 
experiments in 3D, tumoroids were fabricated using the 
plastic compression method modified from [38]. Briefly, 
400 μl of MEM x10 medium were mixed with 3.2 ml 
of rat tail collagen type I (2.20 mg/ml in 0.6%v/v ace-
tic acid; First Link UK Ltd). The mixture was neutral-
ized with 5 M and 1 M NaOH until a color change 
from yellow to pink was observed, and then 6.4 × 106 
cells suspended in 400 μl medium were added to the 
mixture. The resulting solution was placed in a stainless 
steel mould and left to gel for 30 min at room tempera-
ture. The mould containing the gel was then placed on 
a nylon mesh resting on a 165 μm stainless steel mesh 
placed on a 30 nm filter paper. A 176 g plunger was 
placed on top of the gel allowing compression for 30 s 
and the whole compression process was repeated on the 
other side of the gel. The resulting 2.6%w/v collagen 
dense mass [20] was cut in four equal parts with a surgi-
cal scalpel and nested in 1 ml of uncompressed acellular 
collagen hydrogel in 12-well plates. The nested con-
struct was left for 20 min to gel at 37°C. Fully supple-
mented medium (1 ml) was added; cells were starved 
with serum-free media on day 6 and treated with the 
therapeutic formulations on day 7.
For Western blot analysis, 2 × 105 HCT116 cells were 
seeded on 6-well plates and left to grow until 60% con-
fluence. At that point, cells were treated with a range of 
AZD6244 concentrations (0.01–1 μM) either free or 
in nanoparticle formulations for 1 h and then 10 ng/ml 
of EGF were added for 10 min to activate the MAPK 
pathway. Cells were then lysed with 250 μl of radio-
immunoprecipitation assay buffer (Sigma-Aldrich) 
supplemented with protease inhibitors (Roche, Hert-
fordshire, UK) and samples were stored at −20°C until 
required.
Toxicity experiments
For toxicity experiments on cell monolayers, after 24 h 
of starvation (in serum-free media), cells were treated 
with a range of AZD6244 concentrations (0.01–10 μM) 
in free or nanoparticle form, or the equivalent in the 
form of control nanoparticles. Free drug and nanofor-
mulation concentrations were prepared in serum-free 
McCoy’s 5A medium. After 48 h treatment, metabolic 
activity and cell proliferation were determined using 
MTT and total DNA assays, respectively. For the MTT 
assay, 12.5 μl of a 20 mg/ml MTT solution (Sigma-
Aldrich) was added to each well and left for 30 min 
before removing the medium, dissolving the resulting 
crystals in 400 μl of DMSO, incubating for 10 min at 
37ºC and reading the absorbance at 570 nm in a colori-
metric plate reader (Anthos 2010 Standard, Biochrom, 
Cambridge, UK). For the total DNA assay, the Hoechst 
stain total DNA kit (Sigma-Aldrich) was used. Medium 
was removed from each well, 500 μl of DNAse-free 
water added and three freeze–thaw cycles were per-
formed. 100 μl of the resulting solution were added to 
100 μl of a 1:1000 dilution of Hoechst 33298 dye solu-
tion, fluorescence was read immediately after and total 
DNA extrapolated from a standard curve (excitation = 
350 nm, emission = 460 nm) in a Fluoroskan Ascent FL 
(Thermo Labsystems, Warrington, UK).
For toxicity experiments on tumoroids, cells were 
starved on day 6 and treated on day 7 with the same 
range of AZD6244 concentrations than the monolay-
ers. Alamar Blue® assay (Invitrogen, Paisley, UK) was 
used to measure metabolic activity. Concentrated Ala-
mar Blue was diluted at a 1:10 ratio in Phenol Red-
free DMEM medium. Medium was removed from 
wells containing the nested constructs and 1 ml of the 
diluted Alamar Blue® solution was added. Tumoroids 
were then incubated for 4 h in a 37°C, 5% CO
2
/air 
humidified atmosphere, 100 μl of the supernatant was 
transferred to a black 96-well plate and the fluorescence 
read immediately (excitation = 530 nm, emission = 620 
nm) in a Fluoroskan Ascent FL (Thermo Labsystems).
Protein analysis
Protein samples extracted using radioimmunoprecipi-
tation assay buffer were centrifuged at 12000 x g at 
4ºC for 5 min to remove cell debris and total protein 
was quantified using the Lowry protein assay (Ther-
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moscientific, Warrington, UK), at reading absorbance 
750 nm using a Jenway Genova Plus Spectropho-
tometer (Jenway, Staffordshire, UK). After mixing 
with NuPAGE® LDS Sample Buffer (Life technolo-
gies) containing 12.5% β-Mercaptoethanol (Sigma-
Aldrich) protein samples were denatured at 95ºC 
for 5 min, chilled on ice, then loaded in a NuPAGE 
4–12% Bis-Tris polyacrylamide gel (Invitrogen) next 
to a prestained protein ladder (SeeBlue® Prestained, 
Invitrogen). The gel was run at 150 V for 90 min in 
MES SDS running buffer, and transferred to PVDF 
membranes (Immun-Blot® PVDF membrane, Bio-
Rad, Hertfordshire, UK) by immersing the cassette 
in NuPAGE® Transfer Buffer (Life Technologies) 
and running it at 30 V for 75 min. Membranes were 
blocked with 2.5% w/v bovine serum albumin (BSA) 
in PBS-Tween solution and incubated with mouse 
monoclonal anti-pERK (1:1000 dilution) (#9106S, 
Cell signaling, Hitchin, UK) and GAPDH (1:2000 
dilution) (#sc-32233, Santa Cruz Biotechnology, CA, 
USA) antibodies in 1% BSA, followed by hybridiza-
tion using a horseradish peroxidase (HRP)-conjugated 
goat antimouse secondary antibody (1:2000 dilution) 
(#sc-2005, Santa Cruz Biotechnology), developed 
with Bio-Rad Immuno-Star Western C developer 
and visualized using a BioRad Molecular Imager®, 
ChemiDoc™ XRS+ with ImageLab™ Software 
(BioRad).
Penetration studies
Nile red liposomes and micelles were fabricated as indi-
cated above. The fluorescent signal of the solution was 
normalized for all formulations (liposomes, micelles 
and free dye dissolved in DMSO). Confocal micros-
copy was used to focus on an optical plane 300 μm 
deep from the top of the artificial cancer mass (ACM) 
(approximately its core), and images were taken using 
a green laser (543 nm) and a red fluorescence detec-
tor (630 nm). Culture medium was removed and the 
Nile red formulations were added on the surface of the 
tumoroids. Images of the central plane inside the com-
pressed cancer mass were taken over a period of 24 h to 
determine the rate of penetration of each formulation. 
Fluorescent counts were quantified using Image J.
Statistical analysis
Statistical analysis and graphical representations were 
performed using the GraphPad Prism5.0 software. 
Data were analyzed using Student’s t-test and one-way 
ANOVA analysis followed by Dunnet’s or Bonferron-
ni’s post hoc tests for statistical significance. Means and 
standard deviations are represented for each treatment 
group and all statistical analyses were carried out on 
the original data.
Results
DOPE/DC-cholesterol & GCPQ nanoparticles 
encapsulating AZD6244
DOPE/DC-cholesterol liposomes were fabricated 
by dissolving the lipid components and hydrophobic 
cargos (AZD6244, Nile red or none) in a mixture of 
chloroform and methanol (2:1) and evaporating the 
solvents to rehydrate the remaining thin layer. The 
type of cargo did not influence the size or morphology 
of the liposomes, which remained spherical and in the 
same size range, as imaged by TEM (Figure 1A). Lipo-
some sizes ranged between 70 nm and 500 nm with 
the majority at approximately 165 nm, as shown by 
DLS analysis (Figure 2A). Occasionally, DLS analysis 
also revealed a very small peak at 3–6 μm, indicating 
the tendency of these nanoparticles to form aggregates 
in aqueous media. In the case of the control liposomes 
with no cargo, the main peak at 180 nm was very simi-
lar to that observed for the cargo-loaded nanoparticles, 
but with a broader size range (30–1100 nm) (data not 
shown).
 GCPQ micelles were fabricated by tip sonication of 
an aqueous solution containing GCPQ and the hydro-
phobic cargo, or just GCPQ for the control nanopar-
ticles. After an additional centrifugation and filtration 
step to remove nonencapsulated drug, TEM analysis 
revealed a spherical morphology for micelles, but these 
were smaller than the liposomes (Figure 1B); as in the 
case of the liposomes, micelle size was not influenced 
by the type of cargo. As shown by TEM, micelle diam-
eters were on average approximately 30 nm in diameter 
while DLS analysis shows a distinct peak at 350 nm, 
covering from 260 to 550 nm (Figure 2B). This is prob-
ably due to the tendency of GCPQ micelles to form 
aggregates in aqueous media [29]. By contrast, control 
micellar nanoparticles with no cargo formed two dif-
ferent sized aggregates in solution, showing peaks at 9 
and 50 nm in DLS with ranges of 5–12 nm and 40–80 
nm respectively (data not shown).
As measured by HPLC, both drug-loaded nanopar-
ticles yielded AZD6244 concentrations between 0.85 
and 1.15 mM, representing encapsulation efficiencies 
between 45 and 55%.
Nanoformulations increase AZD6244 efficacy 
in monolayers
Human colorectal cancer cells (HCT116) were treated 
with micelles and liposomes containing AZD6244 as 
well as free AZD6244 for 48 h before the total DNA and 
MTT assays were performed. In terms of cellular pro-
liferation (determined by total DNA assay) AZD6244 
treatment resulted in a 21% decrease in proliferation 
at the highest concentration of the drug (1 μM), while 
liposomes and micelles with the same drug load resulted 
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Figure 1. Transmission electron microscopy images of organic nanoparticles. Aqueous suspensions of AZD6244-
loaded nanoparticles were placed on a carbon grid and stained with a 1% aqueous solution of uranyl acetate. 
(A) DOPE/DC-cholesterol liposomes (scale bar: 500 nm, mag 31000×, 80.0 V). (B) GCPQ micelles (scale bar: 100 nm, 
mag 135000×, HV120.0 kV).
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in 61 and 89% inhibition, respectively (Figure 3A; 
p < 0.001). Regarding metabolic activity measured by 
MTT, nanoformulations were clearly more efficient than 
the free drug but the differences were not as pronounced 
(18, 60 and 40% for the free drug, liposomes and 
micelles, respectively) (Figure 3B; p < 0.001). This may 
be due to an increase in metabolic activity by the sur-
viving cells which need to compete less for the nutrients 
in the medium. There was a statistically significant dif-
ference between micelle and liposomal formulations at 
every concentration tested, except at 0.01 μM using the 
proliferation assay and at 0.1 μM when using the MTT 
assay. Interestingly, micelles appeared more toxic accord-
ing to the total DNA assay, while MTT assay revealed 
a higher metabolic activity inhibition in the liposome-
treated group, suggesting differences in the delivery and 
internal processing between these nanoformulations.
To establish whether the above toxicity patterns were 
due to more efficient delivery of AZD6244 into the 
cell, internal processing or merely due to the toxicity 
of the nanoparticle components, a similar experiment 
with water-containing nanoparticles was performed. 
The highest concentration of nanoparticles (equiva-
lent to the concentration used for the 1 μM AZD6244 
treatment) elicited 7 and 25% proliferation inhibition 
for liposomes and micelles, respectively (Figure 3C). 
This suggests that most of the inhibitory effect of the 
nanoformulations is due to a more efficient delivery 
and internal processing of the drug and not due to an 
intrinsic toxicity of the nanoparticle components.
To further confirm delivery of AZD6244 into the 
cytoplasm and specific pharmacological action on the 
target MAPK pathway, Western Blot analysis was per-
formed. Cells were treated with the same drug con-
centrations in the three different delivery forms and 
proteins were separated by size in a polyacrylamide gel. 
Phosphorylated ERK, a common indicator of MEK 
activity, was detected using a monoclonal antibody. 
Densitometry revealed that in all three formulations, 
a dose-dependent reduction in the levels of phosphory-
lated ERK occurred; these decreases were 86, 80 and 
53% for liposomes, micelles and free drug, respec-
tively (Figure 4). This shows that AZD6244 reaches 
its target and elicits a specific response at the protein 
level, and that the delivery is much more efficient 
in nanoformulations compared with the free drug. 
While control GCPQ micelles are significantly more 
toxic than control DOPE/DC-cholesterol liposomes 
(Figure 3C), AZD6244-loaded liposomes elicit more 
inhibition of metabolic activity and MEK1/2 activ-
ity than AZD6244-loaded micelles (Figures 3B & 4), 
suggesting a more efficient delivery of the drug.
GCPQ micelles elicit the highest toxicity in a 3D 
in vitro cancer model
The 3D in vitro cancer model used here consisted of a 
dense collagen core containing the cancer cells (ACM) 
surrounded by an uncompressed collagen hydrogel 
(stromal surround) (Nyga et al. 2013). Tumoroids were 
allowed to mature for 7 days, allowing cancer cells to 
form aggregates, thereby mimicking in vivo avascular 
micrometastases. Treatment with free AZD6244 and 
the nanoformulations was performed for 24, 48 and 
72 h. It is routine to include an extra 24 h incubation 
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Figure 2. Dynamic light scattering analysis of organic nanoparticles. Aqueous suspensions of AZD6244-
loaded nanoparticles were placed in a disposable cuvette and measured three-times (each in one color) for 
15 repeats each for size analysis in a Malvern Nanosizer ZS. (A) AZD6244-loaded DOPE/DC-cholesterol liposomes. 
(B) AZD6244-loaded GCPQ micelles.
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when moving from 2D to 3D cultures to optimize the 
effects of drugs, as more time is needed for the drug to 
reach the cells in 3D and the metabolism in 3D tumor-
oids is also slower (based on data generated from our 
group, not shown). For that reason, when correlating 
the data between both models, the 48 h treatment in 
2D was compared with the 72 h treatment in 3D. Treat-
ment with free AZD6244 and its nanoformulations 
showed increasing efficacy with increasing AZD6244 
concentrations and treatment times. Inhibition of 
metabolic activity started to be significant at 0.1 μM.
Drug efficacy in tumoroids was different from 
monolayers. When comparing the results of metabolic 
activity assays, while the free drug was more effec-
tive in 3D than in 2D (38 vs 18% inhibition), the 
nanoparticle treatments were more effective in 2D (60 
vs 26% inhibition for liposomes and 40 vs 34% inhi-
bition for micelles) (Figure 5C). Overall, micelles were 
more toxic in tumoroids than the other formulations 
(Figure 5). Significant differences were observed at 0.1 
μM AZD6244 and at 24 h, where micelles were supe-
rior to liposomes (Figure 5A: p < 0.01). Furthermore, 
at 1 μM and 48 h, micelles were superior to both lipo-
somes (p < 0.001) and free drug (p < 0.01) (Figure 5B), 
while at 1 μM and 72 h only micelles were only supe-
rior to liposomes (p < 0.05). In the latter treatment, the 
free drug also showed more toxicity than the liposomes 
(p < 0.01), making the liposomes the least effective of 
the three formulations in tumoroids (Figure 5C).
Nanoparticle-mediated delivery is hindered by 
poor penetration into the ACM
In order to further explore the differences in the efficacy 
of nanoparticles for delivery of drug in the two models, 
tumoroids were cultured and matured for 7 days and 
exposed to Nile red-loaded fluorescent nanoparticles. 
The focal plane was set at 300 μm into the ACM core, 
and fluorescence was imaged and measured over time.
These studies revealed a clear size-dependent ability 
of the nanoparticles to penetrate the ACM. The pen-
etration of the free dye control at the ACM core started 
reaching a plateau before 2 h (Figure 6A & C), with a 
fluorescent signal 10-fold higher than the one showed 
by liposomes and micelles after 24 h (Figure 6B & C). 
GPCQ micelles and DOPE /DC-cholesterol lipo-
somes showed a very similar penetration profile, most 
likely due to the fact that they are both cationic.
Discussion
This work explores the effect of cationic organic nano-
carriers loaded with AZD6244 on HCT116 colorectal 
cancer cells cultured both as monolayers and in tumor-
oids. The use of 3D cancer models aims to mimic the 
cell microenvironment found in vivo while still allow-
ing the control of parameters in vitro. AZD6244 has 
been extensively studied in Phase I and II clinical trials 
with promising results, alone and in combination with 
other therapies [39].
Nanoparticle toxicity & AZD6244 delivery
To our knowledge, this is the first report on AZD6244-
carrying nanoparticles, although other MEK inhibi-
tors have been encapsulated in nanoformulations. 
Basu et al. demonstrated that PLGA nanoparticles 
carrying the MEK inhibitor PD98059 successfully 
induced apoptosis and inhibited proliferation of lung 
cancer and melanoma in vitro, and improved the effect 
of cisplatin in melanoma cells in vivo [40]. Similarly, 
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Figure 3. Nanoparticle and free drug toxicity in a 2D in vitro model. HCT116 cells were seeded and maintained 
in serum-free medium for 24 h before treatment with free AZD6244 and AZD6244-loaded nanoparticles (A & B) 
or control nanoparticles (C). After a 48-h treatment, total DNA assay (A) and MTT assay (B & C) were performed. 
Significance: (A) all p < 0.001 except **p < 0.01; (B) all p < 0.001 except *no significance; (C) ***p < 0.001. 
Control: Thin horizontal line.
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a DGL cationic liposome containing a combination 
of the MEK inhibitor PD0325901 and Mcl I-specific 
siRNA reduced KB cells survival in vitro and induced 
79% apoptosis in vivo [41].
Our results demonstrated that DOPE/DC-choles-
terol cationic liposomes exert very little toxicity in the 
absence of AZD6244 (7% inhibition at the highest 
concentration, Figure 3C), which in comparison to the 
AZD6244-loaded liposomes (61% for total DNA and 
60% for metabolic activity, Figure 3A & B) suggests a 
very successful AZD6244 delivery mechanism. On 
the other hand, reports regarding the effect of cationic 
surfaces on cells could explain the toxicity of GCPQ 
nanoparticles in the absence of AZD6244 (25% inhi-
bition at the highest concentration, Figure 3C), which 
were significantly more toxic than the liposomes 
(p < 0.001, Figure 3C), but not nearly as toxic as the 
drug-loaded GCPQ micelles (40% for metabolic 
activity and 89% for total DNA, Figure 3A & B).
Aside from the higher toxicity of GCPQ micelles 
compared with DOPE/DC-cholesterol liposomes, 
both AZD6244-loaded nanoparticles seemed to be 
excellent delivery platforms as determined by prolif-
eration (total DNA assay), metabolic activity (MTT 
assay) and enzyme inhibition (pERK levels). The tox-
icity of both control nanoparticles was significantly 
lower than that of the AZD6244-loaded nanoparticles 
(Figure 3). As determined by Western blot analysis of 
phosphorylated ERK1/2, all three formulations suc-
cessfully inhibited the activity of MEK1/2 (Figure 4). 
The most efficient inhibition was elicited by the lipo-
somal formulation. These results, in combination with 
the much higher cytotoxicity of liposomes and micelles 
compared with the free drug (61, 89 and 21% inhibi-
tion of proliferation, and 60, 40 and 18% inhibition in 
metabolic activity, respectively [Figure 3]) suggest an 
efficient internal processing and delivery to the cyto-
plasm. Specifically, liposomes seem to be the best route 
of delivery in monolayers, since they inhibit metabolic 
activity (Figure 3B) and MEK activity (Figure 4) rather 
more efficiently than both micelles and free drug, even 
though GCPQ micelles show higher toxicity (total 
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Figure 4. Western blot analysis of phosphorylated ERK. HCT116 cells were seeded and starved for 24 h 
before being treated with free AZD6244 and AZD6244-loaded nanoparticles at a range of concentrations for 
60 min followed by the activation of the MAPK pathway by adding 10 ng/ml EGF for 10 min. Cells were lysed, 
protein extracted, quantified and separated using a polyacrylamide gel, transferred to a PVDF membrane and 
phosphorylated ERK and housekeeping gene GAPDH detected with monoclonal antibodies.
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DNA for drug-loaded micelles and MTT for control 
micelles) (Figure 3A & C).
Both DOPE/DC-cholesterol liposomes and GCPQ 
micelles have a positively charged surface. The cat-
ionic nature of these nanoparticles not only facilitates 
nucleic acid loading (as mentioned earlier for the lipo-
somes) but also facilitates the adhesion to the nega-
tively charged cell membrane (through an electrostatic 
interaction) and internalization [22,32,33], leading to 
improved delivery and therapeutic effects. The draw-
back, however, is that a nanoparticle with a surface too 
rich in positive charges can disrupt the membrane [42]. 
The presence of DOPE in this cationic liposomes 
could have the dual function of reducing their toxic-
ity [28] and potentially eliciting an inverted hexago-
nal phase transition that facilitates the delivery to the 
cytoplasm [43]. Aside from their cationic nature, there 
have been reports of liposomal toxicities that may be 
important in the context of their efficacy. For example, 
hybrid liposomes with no cargo have been reported 
to prolong survival in mice with CRC xenografts by 
inducing apoptosis [44]. The adhesion of liposomes 
also causes mechanical stress and local contraction 
of the cell membrane [45]. Compared with these stud-
ies, the liposomes used in our work in the absence of 
AZD6244 showed relatively little toxicity.
However, as a polycation, GCPQ does have a 
stronger positive surface charge that might destabi-
lize the cell membrane to a certain extent and cause 
cytotoxicity even in the absence of the drug. While 
AZD6244-loaded liposomes elicited more prolifera-
tion inhibition than AZD6244-loaded micelles in 
terms of metabolic activity, AZD6244-loaded micelles 
were more efficient according to the total DNA assay 
(89% vs 61%, Figure 3A). This suggests that geno-
toxicity could be an indirect cause of the inhibition 
of cellular proliferation in this system. In a study by 
Shah et al. the effect of a number of nanoparticles 
with different characteristics on DNA was evaluated: 
neutral and anionic nanoparticles did not exhibit 
genotoxic properties while cationic nanoparticles did, 
as demonstrated by the formation of micronuclei. The 
degree of genotoxicity did not correlate to the size or 
molecular weight of the nanoparticles, rather to the 
extent of the positive charges on the surface of the 
nanoparticles [46]. This results support the findings 
reported here of greater nanoparticle toxicity elicited 
by a polycation such as GCPQ. It is worth noting that 
in the same work, the overall cytotoxicity of neutral 
20 nm diameter micelles was higher than that of 180 
nm diameter cationic liposomes, indicating that the 
toxicity of our 30 nm diameter GCPQ micelles com-
pared with the 165 nm diameter DOPE/DC-cho-
lesterol liposomes even in the absence of AZD6244 
could relate to their size.
According to Andar et al. nanoparticle size affects 
the way they are internalized. In their work, larger 
nanoparticles (162.1-nm diameter) tended to be inter-
nalized by clathrin-dependent mechanisms while the 
smallest (40.6-nm diameter) were internalized by 
dynamin-dependent mechanisms [47]. Smallest par-
ticles were internalized 12-fold more efficiently than 
the largest, and the internalization of intermediate-
sized nanoparticles corresponded with a size-depen-
dent pattern. Even though this study was carried out 
with liposomes exclusively, the differences in size 
apply to our DOPE/DCcholesterol liposomes and 
GCPQ micelles.
A fraction of our control micelles (without 
AZD6244) were smaller compared with the AZD6244-
loaded micelles (9 vs 30 nm). This could partly explain 
their toxicity in the absence of AZD6244, since smaller 
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Figure 5. Nanoparticles and free drug toxicity in a collagen-based 3D in vitro model. Cells were seeded in 
hydrogel-nested artificial cancer masses and left to mature and form aggregates for 7 days. Cells were treated 
with AZD6244 and AZD6244-loaded nanoparticles at a range of concentrations for 24 (A), 48 (B) and 72 h (C) 
before Alamar blue® assay was performed.  
*p < 0.05; **p < 0.01; *p < 0.001.  
Control: Thin horizontal line.
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nanoparticles are more easily internalized and can 
even reach the cell nucleus [13]. This is supported by 
the size-dependent cytotoxicity reported by Shah et al. 
mentioned earlier [46]. However, since 30 nm diameter 
GCPQ micelles were small enough to undergo effi-
cient internalization [47], the toxicity of GCPQ control 
micelles is likely to be due to their positively charged 
surface.
Tumoroids as a platform for screening 
nanoformulations
A number of MEK inhibitors have been tested in 3D 
cancer models. These include PD98059 for breast can-
cer cells using Matrigel [48] and GSK1120212 in com-
bination with BRAF and AURKA inhibitors for mela-
noma using a skin reconstruction model [49]. As a free 
drug, the efficacy of AZD6244 has been previously 
tested in a model of melanoma grown within a col-
lagen hydrogel, in combination with the SCR inhibi-
tor saracatinib showing promising results [50]. This 
work differs from our plastic compression approach 
in that cells are cultured in an uncompressed collagen 
matrix, while our model undergoes plastic compres-
sion resulting in a cancer mass with a collagen density 
of 2.6%w/v.
In the present work, treatment with free AZD6244 
was more effective in tumoroids than in the mono-
layers (18% inhibition at 48 h, 1 μM in monolayers 
(Figure 3); 38% inhibition at 72 h, 1 μM in tumor-
oids [Figure 5]). This was especially surprising consid-
ering that the cell density in tumoroids is extremely 
high compared with monolayers, resulting in a drug-
to-cell ratio over 5000-times higher in the monolayer 
experiments, and therefore suggesting very differ-
ent cell behavior between the two models. However, 
this interpretation must be considered as a hypoth-
esis, since the differences are subtle and the time of 
treatment differs between both models.
Previous work with spheroids and other 3D models 
of cancer have shown significant differences in drug 
response compared with monolayer cultures. However 
in most cases, 3D cultures tend to be more resistant 
to antimitotic drugs than monolayers [11,51]. These 
differences are not properly understood, but cells in 
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Figure 6. Nanoparticle penetration into the tumoroids. HCT116 cells were seeded in hydrogel-nested artificial 
cancer masses and left to mature and form aggregates for 7 days. Tumoroids were treated with (A) free Nile red 
dissolved in DMSO and (B) liposomes and micelles containing Nile red. Images were taken through the center of 
the artificial cancer mass over a period of 24 h and (C) fluorescence was quantified using the Image J software.
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both models are certainly subject to different condi-
tions. Some examples are changes in gene expression 
and cell behavior when cells are in contact with each 
other, drug concentration gradients and differential 
proliferation patterns in acidic, hypoxic- or nutrient-
deprived regions of the constructs (Nyga et al. 2013; 
Minchinton & Tannock 2006). 3D cancer models 
mimic these conditions to make cell behavior more 
similar to real tumor tissues [10]. However, the dif-
ferences in drug efficacy between 2D and 3D are 
unpredictable and that highlights the importance 
of 3D testing during drug development. For exam-
ple, although Magdeldin et al. reported a two-fold 
increase of EGFR expression in HT29 cell tumoroids 
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compared with monolayers, the anti-EGFR monoclo-
nal antibody cetuximab elicited a weaker inhibitory 
response in the former [9].
In the present work, the role of the extracellular 
environment in our tumoroid system was simplified to 
a compressed collagen matrix. Therefore, any changes 
in behavior of HCT116 cells are exclusively due to the 
dense collagen microenvironment of the ACM and the 
cellular 3D conformation. There is evidence that these 
parameters are enough to cause radical changes in cell 
behavior [12].
The greater effect of free AZD6244 in tumoroids 
compared with monolayers, combined with the supe-
rior delivery of the drug observed with the nanopar-
ticles in monolayers, suggest that the reduction in 
efficacy observed in the nanoparticle treatment of the 
tumoroids (60% for liposomes and 40% for micelles 
in monolayers (Figure 3B) vs 26% inhibition for lipo-
somes and 34% for micelles in tumoroids [Figure 5C]) 
was not caused by the drug itself. The most likely 
scenario to explain the suboptimal efficacy of these 
liposomes and micelle aggregates in tumoroids is their 
localization within the ACM. Their diffusion toward 
the core may be partly limited by their large size, pos-
sible interactions with the collagen matrix and the 
uptake by cancer cell aggregates at the outer bound-
ary of the ACM. The core of the ACM is representa-
tive of cancer cells hundreds of micrometers distant 
from a blood vessel in vivo, to which the drugs have 
limited access [52]. This hypothesis is supported by 
our penetration studies (Figure 6). It is worth not-
ing that additional functionalization of the surface 
with antibodies or PEG, which are traditional surface 
modifications for in vivo studies, would make these 
nanoparticles even larger. Furthermore, the presence 
of serum proteins/glycoproteins would also contribute 
to nanoparticle agglomeration.
The efficacy of micelles (or micelle aggregates) 
in tumoroids compared with the liposomes is closer 
to, and in some cases more effective than, the free 
drug. While the efficacy of the free drug could be 
due to a much better penetration, the higher effi-
cacy of micelles could be due to their cationic toxic-
ity (Figure 3C), however limited to the periphery. It is 
also possible that cells in the periphery of the ACM 
are more metabolically active than those of the core, 
due to limited diffusion of nutrients across the dense 
cancer mass. This would favor the toxicity of the 
nanoparticles that, however remaining in the outer 
layers of the ACM, have a greater inhibitory effect on 
metabolic activity.
Molecular weight, solubility, shape and other physi-
cochemical characteristics of a drug influences its 
diffusion through tissue [52]. It has been suggested 
for large molecules such as antibodies that size could 
affect their ability to penetrate 3D models [9,53]. In the 
case of antibodies, not only their size but their ability 
to bind to surface receptors could hinder their pen-
etration by sequestration in the outer layers of cells. 
Similarly, the very uptake of drugs in the periphery 
of the structure could limit the penetration to deeper 
layers [52]. Penetration becomes especially important in 
the case of nanoparticles, which size far exceeds that 
of drugs, particularly small molecules. Huang et al. 
demonstrated that different sizes of gold nanoparticles 
have the ability to penetrate into tumor spheroids in 
a size-dependent manner. Additionally, the smallest 
particles (2–6 nm) were able to reach the nucleus while 
the largest (15 nm) were confined to the cytoplasm of 
cells [13].
Conclusion
Organic cationic nanoparticles such as GCPQ 
micelles and DOPE/DC-cholesterol liposomes 
appear to be excellent carriers for hydrophobic small 
molecules such as AZD6244. They are successfully 
internalized by cells grown in monolayers and deliver 
the drug into the cell more efficiently than the free 
drug. While AZD6244 as a free drug seems to elicit 
a higher inhibitory response in tumoroids compared 
with monolayers, the size and nature of our nanocar-
riers limit their penetration into the deeper regions 
of the tumoroid model and therefore hinder their 
therapeutic capacity. In spite of this, GCPQ micelles 
showed the highest toxicity in tumoroids, probably 
due to a higher intrinsic toxicity caused by their size 
and surface charge. While further work is needed to 
fully understand their behavior and efficacy in 3D 
models, these preliminary studies point at GCPQ 
micelles as the most beneficial formulation for a phar-
maceutical scientist. To our knowledge, this is the first 
time AZD6244 has been tested as a nanoformulation, 
or indeed any nanocarrier has been tested in a natural 
scaffold-based 3D cancer model. These results illus-
trate the efficacy of cationic organic nanocarriers for 
hydrophobic drug delivery and highlight the impor-
tance of accounting for the tumor microenvironment 
during drug development, particularly in the case of 
nanoformulations.
Future perspective
In this work, two of the most promising approaches 
to the fields of drug development and drug delivery 
converge: the use of nanocarriers as drug delivery plat-
forms and the use of 3D in vitro models for drug test-
ing. In the near future, the development of most newly 
discovered drugs will include testing in 3D models at 
some point during the preclinical stages and the use of 
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animals will be significantly reduced due to this screen-
ing process. Similarly, the field of nanomedicine will 
continue to expand since many initially promising mol-
ecules whose progress was interrupted due to adverse 
biological interactions and physicochemical limitations 
can be regenerated for new treatment possibilities.
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Executive summary
DOPE/DC-cholesterol and GCPQ nanoparticles encapsulating AZD6244
• Both nanocarriers were successful in the encapsulation of hydrophobic cargo AZD6244 and show consistent 
sizes and encapsulation efficiencies.
Nanoparticle toxicity and AZD6244 delivery
• Liposomes and micelles containing AZD6244 deliver the drug more efficiently than a solution of the free drug. 
This is demonstrated by proliferation assays as well as a reduction in the activity of the target protein.
• Only GCPQ micelles show a moderate toxicity without the cargo, which could be attributed to their strong 
cationic nature.
Tumoroids as a platform for screening nanoformulations
• The significant differences in treatment efficacy between monolayers and tumoroids suggest that 3D cancer 
models should be included in the drug development process, particularly in the case of nanoparticles.
Nanoparticle-mediated delivery is hindered by poor penetration into the artificial cancer mass
• Experiments on tumoroids show that the efficacy of large cationic nanoparticles is limited due to a poor 
diffusion through the cancer mass.
• However, the superior toxicity of GCPQ micelles over the other formulations makes it the most effective on 
the 3D model.
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